ISPOR 17th Annual European Congress

The PHARMO team has been present at the ISPOR Annual European Congress in Amsterdam, the Netherlands, November 8-12, 2014.

We are pleased to announce that seven of our studies have been presented.

Oral presentation:

- Follow-up autoantibody testing and healthcare utilization among patients with (sustained) celiac disease activity in The Netherlands (HS1)

Poster presentations:

- Trend in prevalence and distribution of diabetes mellitus type I and type II in The Netherlands (PDB30)
- Type 2 diabetes treatment patterns across Europe (PDB157)
- Development of a collaborative European pharmacoepidemiologic post-authorization safety study (PASS) programme examining rivaroxaban use in routine clinical practice (PCV6)
- Incidence and prevalence of COPD by GOLD 2013 classification in The Netherlands (PRS12)
- Treatment patterns and outcomes of patients diagnosed with ovarian cancer in The Netherlands: a registry study (PCN232)
- Systemic treatment of metachronous metastases after curative treatment of breast cancer (PCN279)

Pharmaceutical Users Software Exchange Annual Conference

PHARMO was present at the PhUSE Annual Conference. The PhUSE 2014 Conference was held from 12th to 15th October in London, UK. The main theme focussed on "Data Transparency". This hot topic was already addressed in some streams of the 2013 conference as well as by one of our keynote speakers who explained how transparency would help to improve patients’ lives.

Berber Snoeijer, who is R&D Manager at the PHARMO Institute, led the stream Health Outcomes Research & Epidemiology (HE). The HE stream was dedicated to specific programming and analysis issues related to epidemiology and health outcomes research. This included data (quality) standards, data analysis standards, big data handling, patient reported outcomes, compliance assessments, epidemiological analysis, economic evaluation and more.

Please click here for the abstract of Berber Snoeijer’s presentation entitled "Simple and efficient matching algorithms for case-control matching".
30th International Conference on Pharmacoepidemiology & Therapeutic Risk Management

PHARMO contributed to a study which was presented at the 30th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, in Taipei, October 23-27, 2014.

The study was entitled ‘Hepatotoxicity with pazopanib for renal cell carcinoma in the post-approval setting’.

The International Society for Pharmacoepidemiology (ISPE) is a non-profit international professional membership organization dedicated to advancing the health of the public by providing a forum for the open exchange of scientific information and for the development of policy; education; and advocacy for the field of pharmacoepidemiology, including pharmacovigilance, drug utilization research, outcomes research, comparative effectiveness research, and therapeutic risk management.

For more details, click here.